About the Company

Mclinica is a health tech platform that has regional offices located in Singapore, Indonesia, Philippines and Cambodia

Context / Challenge

I was the primary product manager managing seven (7) patient assistance programs commissioned by clients, are available in both android and iOs and deployed in the following markets: Singapore, Hong Kong, Indonesia, and Malaysia.

One of the existing clients that we had was thinking of creating a consolidated patient assistance program (PAP) in HongKong consisting of the different PAPs from different pharmaceutical companies.

The initial proposal was for the client and our team to conduct user research to be able to better design the program flow that would best be suitable to the patients. Client refused saying that user research would take a significant amount of time, not to mention that it would cost additional money to implement.

A better product, you say? What’s that?

A better product, you say? What’s that?

My Proposed Solution

Given that the client is hesitant to conduct user research, I took it upon myself to conduct secondary research to understand how patients in Hong Kong are generally applying for patient assistance programs or subsidies by visiting websites of the partner NGOs of these pharmaceutical companies in charge of implementing the manual version of the PAPs.

I mapped out their manual processes using a flow diagram, and then studied the different requirements per PAP (note: luckily, I was able to read some Chinese characters) to be able to find the commonalities and design a flow that would make the most sense both to the patients and the NGOs that would eventually manage the digital PAPs.

After I created the product flow and initially created a wireframe, I collaborated with the UI/UX to even make the design and experience easier for the patients.

Results

I then presented the initial mocks to the client to which the client was very satisfied, and was on track for development after (most likely a lengthy) discussion with compliance and the rest of the pharmaceutical companies.